Salarius Pharmaceuticals is a clinical-stage biotechnology company developing epigenetic-based cancer treatments. It develops Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma.